^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Epkinly (epcoritamab-bysp)

    i
    Other names: GEN-3013, DuoBody-CD3xCD20, Duobody-CD3-CD20, ABBV-GEN3013, ABBV-GMAB-3013, GEN3013
    Company:
    AbbVie, Genmab
    Drug class:
    CD20 inhibitor, CD3 agonist
    Related drugs:
    1d
    Low Dose Epcoritamab Plus GemOx in R/R DLBCL (clinicaltrials.gov)
    P2, N=10, Recruiting, Hospital Universitario Dr. Jose E. Gonzalez
    New P2 trial
    |
    gemcitabine • oxaliplatin • Epkinly (epcoritamab-bysp)
    8d
    Bispecific Antibodies in B-Cell Lymphomas: Mechanisms, Efficacy, Toxicity, and Management. (PubMed, Medicina (Kaunas))
    This review examines CD20 × CD3 bispecific antibodies (BsAbs) like mosunetuzumab, epcoritamab, odronextamab, and glofitamab, which link malignant B-cells and T-cells, thus inducing targeted tumor lysis...This review details their mechanisms, grading, and management, including the use of tocilizumab and corticosteroids...Expert recommendations for antimicrobial prophylaxis, including herpes and varicella zoster virus, pneumocystis, and immunoglobulin supplements are crucial for mitigating these risks. While BsAbs offer an "off-the-shelf" advantage, balancing their efficacy with comprehensive toxicity management is crucial for maximizing patient outcomes.
    Review • Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Epkinly (epcoritamab-bysp) • Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm) • Ordspono (odronextamab)
    8d
    MOONSHOT: CLL11 - A study to evaluate the efficacy of Epcoritamab consolidation in high genomic risk and Measurable Residual Disease (MRD)-positive Chronic Lymphocytic Leukaemia (CLL) patients after first-line venetoclax and obinutuzumab (ACTRN12625000387426)
    P2, N=38, Recruiting, Australasian Leukaemia and Lymphoma Group (ALLG) | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date • Minimal residual disease
    |
    TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus)
    |
    TP53 mutation • Chr del(11q)
    |
    clonoSEQ
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Epkinly (epcoritamab-bysp)
    17d
    Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome (clinicaltrials.gov)
    P1, N=5, Active, not recruiting, National Heart, Lung, and Blood Institute (NHLBI) | Recruiting --> Active, not recruiting | N=30 --> 5
    Enrollment closed • Enrollment change
    |
    Epkinly (epcoritamab-bysp)
    17d
    WWU23_0006: Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) (2023-509861-19-01)
    P1/2, N=104, Recruiting, Universitaet Muenster
    New P1/2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Epkinly (epcoritamab-bysp) • Zynlonta (loncastuximab tesirine-lpyl)
    17d
    Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=34, Active, not recruiting, Northwestern University | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD4 (CD4 Molecule)
    |
    lenalidomide • Epkinly (epcoritamab-bysp)
    17d
    DS3790-076: A First-in-Human Trial of DS3790a in Participants with Hematological Malignancies. (2025-522595-87-00)
    P1/2, N=30, Not yet recruiting, Daiichi Sankyo Inc.
    New P1/2 trial • First-in-human
    |
    Rituxan (rituximab) • Epkinly (epcoritamab-bysp)
    21d
    EPCORE CLL-1: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (clinicaltrials.gov)
    P1/2, N=195, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting | N=424 --> 195
    Enrollment closed • Enrollment change
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Jaypirca (pirtobrutinib) • Epkinly (epcoritamab-bysp)
    23d
    E-REVRI: Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab (clinicaltrials.gov)
    P2, N=60, Recruiting, The Lymphoma Academic Research Organisation | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • lenalidomide • Epkinly (epcoritamab-bysp)
    1m
    Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=43, Not yet recruiting, City of Hope Medical Center
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    gemcitabine • Rituxan (rituximab) • oxaliplatin • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    1m
    Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (clinicaltrials.gov)
    P2, N=33, Suspended, City of Hope Medical Center | Recruiting --> Suspended
    Trial suspension
    |
    Tazverik (tazemetostat) • Epkinly (epcoritamab-bysp)
    2ms
    T-cell engaging antibodies for B-cell lymphomas. (PubMed, Semin Hematol)
    This review focused on 4 CD20 × CD3 BsAbs, as well as surovatamig, a CD19 × CD3 BsAb currently under investigation that has demonstrated promising efficacy against relapsed/refractory B-cell lymphomas. All 4 CD20 × CD3 BsAbs are approved as third-line and beyond therapies: mosunetuzumab for follicular lymphoma (FL), glofitamab for diffuse large B-cell lymphoma (DLBCL), and epcoritamab and odronextamab for both FL and DLBCL (the latter in European Union only)...Multiple studies are currently evaluating these agents in both the relapsed/refractory and frontline settings, either as monotherapy or in combination with other agents. This review summarizes the efficacy and safety of each agent across B-cell lymphoma subtypes, along with their dosing schedules and CRS mitigation strategies.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Epkinly (epcoritamab-bysp) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm) • Ordspono (odronextamab) • surovatamig (AZD0486)